Key facts
- AIRNA’s last known valuation is $339.0M (Mar 2025).
- It has raised $245.0M; the latest was Early Stage VC ($155.0M) in Mar 2025.
- Notable investors include Alexandria Venture Investments, ARCH Venture Partners, Venrock, Forbion, RTW Investments — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for AIRNA
- ·The full record, as it builds
Funding rounds
No funding rounds for AIRNA are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AIRNA
Developer of a ribonucleic acid (RNA) editing platform designed for healthcare professionals. The company's platform is developing RNA editing therapeutics created to maximize therapeutic properties and address novel targets, enabling patients to get a cure for rare and common diseases.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2021
- Employees
- 50
- Website
- airna.com/
- Ownership
- Privately Held (backing)
AIRNA doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AIRNA shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AIRNA in its N-PORT filings yet. We sweep new filings monthly.